Literature DB >> 8902262

A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102, and P450 108.

M J de Groot1, N P Vermeulen, J D Kramer, F A van Acker, G M Donné-Op den Kelder.   

Abstract

Cytochromes P450 (P450s) constitute a superfamily of phase I enzymes capable of oxidizing and reducing various substrates. P450 2D6 is a polymorphic enzyme, which is absent in 5-9% of the Caucasian population as a result of a recessive inheritance of gene mutations. This deficiency leads to impaired metabolism of a variety of drugs. All drugs metabolized by P450 2D6 contain a basic nitrogen atom, and a flat hydrophobic region coplanar to the oxidation site which is either 5 or 7 A away from the basic nitrogen atom. The aim of this study was to build a three-dimensional structure for the protein and more specifically for the active site of P450 2D6 in order to determine the amino acid residues possibly responsible for binding and/ or catalytic activity. Furthermore, the structural features of the active site can be implemented into the existing small molecule substrate model, thus enhancing its predictive value with respect to possible metabolism by P450 2D6. As no crystal structures are yet available for membrane-bound P450s (such as P450 2D6), the crystal structures of bacterial (soluble) P450 101 (P450cam), P450 102 (P450BM3), and P450 108 (P450terp) have been used to build a three-dimensional model for P450 2D6 with molecular modeling techniques. Several important P450 2D6 substrates were consecutively docked into the active site of the protein model. The energy optimized positions of the substrates in the protein agreed well with the original relative positions of the substrates within the substrate model. This confirms the usefulness of small molecule models in the absence of structural protein data. Furthermore, the derived protein model indicates new leads for experimental validation and extension of the substrate model.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8902262     DOI: 10.1021/tx960003i

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  7 in total

Review 1.  Modeling kinetics of subcellular disposition of chemicals.

Authors:  Stefan Balaz
Journal:  Chem Rev       Date:  2009-05       Impact factor: 60.622

2.  Evidence that serine 304 is not a key ligand-binding residue in the active site of cytochrome P450 2D6.

Authors:  S W Ellis; G P Hayhurst; T Lightfoot; G Smith; J Harlow; K Rowland-Yeo; C Larsson; J Mahling; C K Lim; C R Wolf; M G Blackburn; M S Lennard; G T Tucker
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

3.  Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents.

Authors:  D Sanglard; F Ischer; L Koymans; J Bille
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

4.  Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6.

Authors:  G P Hayhurst; J Harlow; J Chowdry; E Gross; E Hilton; M S Lennard; G T Tucker; S W Ellis
Journal:  Biochem J       Date:  2001-04-15       Impact factor: 3.857

Review 5.  Insights into drug metabolism by cytochromes P450 from modelling studies of CYP2D6-drug interactions.

Authors:  J-D Maréchal; C A Kemp; G C K Roberts; M J I Paine; C R Wolf; M J Sutcliffe
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

6.  Ab initio calculations on iron-porphyrin model systems for intermediates in the oxidative cycle of cytochrome P450s.

Authors:  M J de Groot; R W Havenith; H M Vinkers; R Zwaans; N P Vermeulen; J H van Lenthe
Journal:  J Comput Aided Mol Des       Date:  1998-03       Impact factor: 3.686

Review 7.  Descriptors of Cytochrome Inhibitors and Useful Machine Learning Based Methods for the Design of Safer Drugs.

Authors:  Tyler C Beck; Kyle R Beck; Jordan Morningstar; Menny M Benjamin; Russell A Norris
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.